Common use of Development of Companion Diagnostics Clause in Contracts

Development of Companion Diagnostics. In connection with the Development or Commercialization of any Licensed Product for which the JSC has approved a Territory-Specific Development Plan (as applicable) contemplating the Development of one or more companion diagnostic products to be used in connection with such Licensed Product (each a “Companion Diagnostic”), Zai may elect to Develop one or more Companion Diagnostics solely in the Territory. Unless otherwise allocated to Zai under a Global Development Plan for a Licensed Product, Blueprint will be responsible for Developing Companion Diagnostics for Licensed Products if such Companion Diagnostics are to be used with one or more Licensed Products inside and outside of the Territory. If JSC determines that Zai will Develop a Companion Diagnostic for use with the Commercialization of any Licensed Product in the Territory, then Zai will be responsible [****]. Without limiting ▇▇▇’s reimbursement obligations under Section 5.13 (Responsibility for Development Costs) (which obligations pertain to the Development of each Licensed Product, including the cost to purchase Companion Diagnostics [****] to screen patients in connection with the Development of such Licensed Products), Blueprint will be responsible for [****] Notwithstanding Blueprint’s responsibility for [****] if Zai wishes to use any Companion Diagnostic Developed by Blueprint in connection with ▇▇▇’s Commercialization of any Licensed Product in the Territory, then Zai will reimburse Blueprint for: (a) [****] that are related to the Development of Companion Diagnostics for use with a Licensed Product solely in the Territory [****] and (b) with respect to [****] that are related to the Development of Companion Diagnostics for use [****] the Territory [****].

Development of Companion Diagnostics. In connection with the Development or Commercialization of any Licensed Collaboration Product for which the JSC has approved a Territory-Specific Development Plan (as applicable) contemplating the Development of one or more companion diagnostic products to be used in connection with such Licensed Collaboration Product (each a “Companion Diagnostic”), Zai CStone may elect to Develop one or more Companion Diagnostics solely in the Territory. Unless otherwise allocated to Zai CStone under a Global Development Plan for a Licensed Collaboration Product, Blueprint will be responsible for Developing Companion Diagnostics for Licensed Collaboration Products if such Companion Diagnostics are to be used with one or more Licensed Collaboration Products inside and outside of the Territory. If JSC determines that Zai CStone will Develop a Companion Diagnostic for use with the Commercialization of any Licensed Collaboration Product in the Territory, then Zai CStone will be responsible for [****]. Without limiting ▇▇▇CStone’s reimbursement obligations under Section 5.13 5.10 (Responsibility for Development Costs) (which obligations pertain to the Development of each Licensed Collaboration Product, including the cost to purchase Companion Diagnostics [****] to screen patients in connection with the Development of such Licensed Collaboration Products), Blueprint will be responsible for [****] ]. Notwithstanding Blueprint’s responsibility for [****] ], if Zai CStone wishes to use any Companion Diagnostic Developed by Blueprint in connection with ▇▇▇CStone’s Commercialization of any Licensed Collaboration Product in the Territory, then Zai CStone will reimburse Blueprint for: (a) [****] that are related to the Development of Companion Diagnostics for use with a Licensed Collaboration Product solely in the Territory [****] ]; and (b) with respect to [****] that are related to the Development of Companion Diagnostics for use [****] both inside and outside of the Territory [***] (i) [***], and (ii) [***].